EFG Asset Management North America Corp. decreased its position in Repligen Co. (NASDAQ:RGEN - Free Report) by 13.6% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 19,297 shares of the biotechnology company's stock after selling 3,026 shares during the period. EFG Asset Management North America Corp.'s holdings in Repligen were worth $2,778,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Raymond James Financial Inc. purchased a new position in Repligen during the fourth quarter valued at $52,492,000. Allspring Global Investments Holdings LLC raised its position in shares of Repligen by 79.9% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 457,065 shares of the biotechnology company's stock worth $65,395,000 after purchasing an additional 203,011 shares during the last quarter. DF Dent & Co. Inc. lifted its stake in Repligen by 31.0% in the 3rd quarter. DF Dent & Co. Inc. now owns 590,321 shares of the biotechnology company's stock valued at $87,852,000 after buying an additional 139,615 shares in the last quarter. Segall Bryant & Hamill LLC acquired a new stake in Repligen in the 4th quarter worth about $19,021,000. Finally, Two Sigma Advisers LP increased its stake in Repligen by 421.9% during the 3rd quarter. Two Sigma Advisers LP now owns 126,300 shares of the biotechnology company's stock worth $18,796,000 after buying an additional 102,100 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.
Repligen Trading Down 2.7 %
Shares of NASDAQ RGEN traded down $3.71 during midday trading on Friday, reaching $133.41. 856,653 shares of the stock were exchanged, compared to its average volume of 673,469. The stock has a market capitalization of $7.49 billion, a P/E ratio of -261.59, a PEG ratio of 4.54 and a beta of 0.95. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. The company has a 50 day simple moving average of $154.21 and a 200 day simple moving average of $148.15. Repligen Co. has a twelve month low of $113.50 and a twelve month high of $184.98.
Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, beating the consensus estimate of $0.41 by $0.03. The business had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. As a group, equities analysts expect that Repligen Co. will post 1.72 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Several research firms have recently weighed in on RGEN. HC Wainwright restated a "buy" rating and issued a $180.00 target price on shares of Repligen in a research report on Friday, February 21st. Royal Bank of Canada raised their price objective on Repligen from $203.00 to $205.00 and gave the company an "outperform" rating in a report on Friday, February 21st. Canaccord Genuity Group upped their target price on shares of Repligen from $165.00 to $170.00 and gave the stock a "hold" rating in a report on Friday, February 21st. JPMorgan Chase & Co. raised their price target on shares of Repligen from $190.00 to $200.00 and gave the stock an "overweight" rating in a research note on Friday, February 21st. Finally, Evercore ISI assumed coverage on shares of Repligen in a research note on Tuesday, March 18th. They set an "in-line" rating and a $155.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $178.64.
Read Our Latest Stock Analysis on RGEN
Insider Transactions at Repligen
In related news, Director Margaret Pax acquired 250 shares of the business's stock in a transaction dated Monday, March 17th. The shares were acquired at an average price of $150.69 per share, with a total value of $37,672.50. Following the completion of the transaction, the director now owns 1,043 shares of the company's stock, valued at $157,169.67. The trade was a 31.53 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 1.20% of the company's stock.
Repligen Company Profile
(
Free Report)
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
Further Reading
Before you consider Repligen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.
While Repligen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
